# Revel Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/revel-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.revelpharmaceuticals.com
- Total disclosed funding: $5.8M
- Latest round: Seed (Feb 23, 2022)
- Investors on record: 3

## About

Based in California, US, and founded in 2019 by CEO Aaron Cravens, and Nicholas A. Delateur, Revel Pharmaceuticals Inc. operates as a developer of therapeutics for chronic diseases of aging like osteoarthritis, cardiovascular disease, diabetes, and more. In February 2022, Revel Pharmaceuticals Inc. raised USD 5.75 million in seed funding co-led by KIZOO Technology Ventures and Starbloom Capital, with participation from Tubus LLC.

Revel Pharmaceuticals develops biotechnology therapeutic enzymes that help in degrading age-associated molecule damage, which is caused by different diseases of aging, such as cardiovascular disease, kidney disease, osteoarthritis, complications of diabetes, and skin aging.

The company plans to use its proceeds from March 2022 funding to further the expansion of its enzymatic repair pipeline and crosslink-breakers.

## Funding rounds

- Seed, Feb 23, 2022, $5.8M — KIZOO Technology Ventures, Tubus Management, Starbloom Capital

## Investors

- KIZOO Technology Ventures (https://capitalatlas.ai/funds/kizoo-technology-ventures) — Seed
- Tubus Management — Seed
- Starbloom Capital (https://capitalatlas.ai/funds/starbloom-capital) — Seed